MedTrace Logo

Clinical Study of IBI362 in Healthy Chinese Male Subjects

NCT04773977 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2021-07-08

No results posted yet for this study

Summary

This is a study to evaluate the pharmacokinetic characteristics and safety of IBI362 lyophilized powder and IBI362 liquid formulation in healthy Chinese male subjects.

Conditions

  • Overweight/Obesity

Interventions

DRUG

IBI362 liquid formulation

Administered by subcutaneous injection

DRUG

IBI362 lyophilized powder

Administered by subcutaneous injection

Sponsors & Collaborators

  • Innovent Biologics (Suzhou) Co. Ltd.

    lead INDUSTRY

Principal Investigators

  • Jian Li · The Sceond Affiliated Hospital of Nanchang University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-03-03
Primary Completion
2021-03-09
Completion
2021-06-17

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04773977 on ClinicalTrials.gov